Neither medication truly "does not" increase heart rate—both dopamine and dobutamine can increase heart rate, but dobutamine generally increases heart rate to a lesser extent than dopamine and is the better choice when minimizing chronotropic effects is desired.
Comparative Chronotropic Effects
Dobutamine
Dobutamine produces dose-dependent positive chronotropic effects but to a lesser degree than other catecholamines 1. The ESC Guidelines explicitly state that "heart rate is generally increased in a dose-dependent manner to a lesser extent than with other catecholamines" 1. The FDA drug label confirms dobutamine produces "comparatively mild chronotropic" effects and notes that "tachycardia is occasionally observed" rather than routinely 2.
Key characteristics:
- At therapeutic doses (2-20 mcg/kg/min), heart rate increases are typically modest 3, 4
- Clinical studies show approximately 10% of patients experience heart rate increases of 30 beats/minute or more 2
- Critical caveat: In patients with atrial fibrillation, dobutamine can facilitate AV conduction and cause undesirable tachycardia 1
Dopamine
Dopamine's chronotropic effects are dose-dependent and more pronounced:
- At low doses (<2-3 mcg/kg/min): Minimal effect on heart rate 1
- At moderate doses (3-5 mcg/kg/min): β-adrenergic stimulation begins, increasing heart rate 1
- At doses >5-6 mcg/kg/min: Heart rate increases significantly 1
Multiple research studies confirm dopamine causes greater heart rate increases than dobutamine at comparable inotropic doses 5, 6, 7, 8.
Clinical Evidence Comparison
The most relevant comparative data comes from direct head-to-head studies:
In severe heart failure patients: Dobutamine (7.5 mcg/kg/min) maintained cardiac output improvement without changing heart rate, while dopamine (4 mcg/kg/min) increased heart rate by 12% 7
Post-cardiac surgery: At 5.0 mcg/kg/min, both drugs increased cardiac index without changing heart rate, but at 7.5 mcg/kg/min, dobutamine continued improving cardiac output without tachycardia while dopamine did not 6
Systematic analysis: The 2008 ESC Guidelines emphasize that "dopamine and dobutamine should be used with caution in patients with a heart rate >100 b.p.m." 3, 4, but this warning applies more critically to dopamine at higher doses
Practical Clinical Algorithm
When heart rate control is a priority:
First-line choice: Dobutamine (2-10 mcg/kg/min)
- Provides inotropic support with minimal chronotropic effect
- Monitor for tachycardia, especially in atrial fibrillation
Avoid or use cautiously: Dopamine at >5 mcg/kg/min
- Reserve for hypotensive patients requiring vasopressor support
- Accept that heart rate increases are likely at therapeutic doses
Special consideration: If baseline heart rate >100 bpm, both agents require extreme caution 3, 4
Important Caveats
- Neither agent is truly "heart rate neutral"—both have chronotropic potential 2
- The question of which "does not" increase heart rate is somewhat misleading; the correct framing is which increases it less
- Individual patient responses vary significantly based on underlying pathophysiology, baseline sympathetic tone, and concurrent medications (especially β-blockers) 1, 4
- Tachycardia with either agent may be a dose-limiting adverse effect 1
Bottom line for clinical practice: If you must choose an inotrope while minimizing heart rate increases, select dobutamine at lower doses (2-7.5 mcg/kg/min). However, recognize that complete avoidance of chronotropic effects is unrealistic with either agent 1, 2.